


## Steroid sulfatase/17 $\beta$ -HSD1-IN-4

Cat. No.:	HY-151202
Molecular Formula:	C <sub>18</sub> H <sub>17</sub> N <sub>3</sub> O <sub>4</sub> S <sub>2</sub>
Molecular Weight:	403.48
Target:	Steroid Sulfatase
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Steroid sulfatase/17 $\beta$ -HSD1-IN-4 (compound 37) is a dual inhibitor of steroid sulfatase (STS) and 17 $\beta$ -hydroxysteroid dehydrogenase type 1 (17 $\beta$ HSD1). Steroid sulfatase/17 $\beta$ -HSD1-IN-4 irreversibly inhibits hSTS activity with an IC <sub>50</sub> value of 63 nM. Steroid sulfatase/17 $\beta$ -HSD1-IN-4 can be used in the study of endometriosis and other estrogen-dependent diseases <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 63 nM (hSTS) <sup>[1]</sup> .
In Vitro	Steroid sulfatase/17 $\beta$ -HSD1-IN-4 (compound 37) (0-1100 nM, 24 h) inhibits human steroid sulfatase (hSTS) with an IC <sub>50</sub> value of 63 nM and acts on irreversible inhibition of hSTS with an IC <sub>50</sub> value of 60 nM in T47D human breast cancer cells <sup>[1]</sup> . Steroid sulfatase/17 $\beta$ -HSD1-IN-4 (compound 37) (20 $\mu$ M, 48 h) inhibits HEK-293 cells growth by 15.1% at a concentration of 20 $\mu$ M with low cytotoxicity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Abdelrahman Mohamed, et al. Dual Targeting of Steroid Sulfatase and 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis. J Med Chem. 2022 Aug 22.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA